Corbus Pharmaceuticals Holdings, Inc. (CRBP) Tuesday announced FDA clearance for its investigational new drug or IND application of CRB-601, a TGFß blocking monoclonal antibody targeting the integrin avß8.
The Oncology company said CRB-601 could overcome tumor immune exclusion and enhance the activity of immune checkpoint inhibitors in vivo. The company expects to enroll the first participant in a Phase 1 study in the first half of 2024.
Corbus said it will initiate Phase 1 First-in-Human trial of CRB-601 and to enroll the first participant in the first half of this year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.